

Appendix to:**Title:**

Type-Specific Concurrent Anogenital HPV Detection among Young Women and MSM attending Dutch Sexual Health Clinics.

Authors:

Johannes M.A. Kusters^{1,2}

Janneke C.M. Heijne¹

Birgit H.B. van Benthem¹

Audrey J. King¹

Maarten F. Schim van der Loeff^{2,3}

¹*Centre for Infectious Diseases Control, National Institute for Public Health and the Environment, Bilthoven, the Netherlands*

²*Institute for Infection and Immunity (AII), Amsterdam UMC, Amsterdam, the Netherlands*

³*Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands*


Supplementary Table 1: Type-specific prevalence for genital, anal and concurrent detected HPV infection, young women and MSM recruited at sexual health clinics in 2009 - 2019 in the Netherlands

| HPV type | Women (n=1,492) | | | MSM (n=614) | | |
|--------------------------------|---|--------------------------------------|-------------------------------|---|--------------------------------------|-------------------------------|
| | Genital infection ¹ n (%) | Anal infection ² n (%) | Concurrent infection n (%) | Genital infection ¹ n (%) | Anal infection ² n (%) | Concurrent infection n (%) |
| Any type-specific ³ | 1,149 (77.0) | 693 (46.5) | 607 (40.7) | 194 (31.6) | 301 (49.0) | 64 (10.4) |
| High risk types | | | | | | |
| HPV 16 | 122 (8.2) | 57 (3.9) | 46 (3.1) | 21 (3.4) | 55 (9.0) | 7 (1.1) |
| HPV 18 | 67 (4.5) | 33 (2.2) | 21 (1.4) | 21 (3.4) | 46 (7.5) | 8 (1.3) |
| HPV 31 | 139 (9.3) | 65 (4.4) | 45 (3.0) | 12 (2.0) | 35 (5.7) | 3 (0.5) |
| HPV 33 | 60 (4.0) | 34 (2.3) | 22 (1.5) | 6 (1.0) | 19 (3.1) | 0 (0.0) |
| HPV 35 | 39 (2.6) | 31 (2.1) | 19 (1.3) | 4 (0.7) | 14 (2.3) | 1 (0.2) |
| HPV 39 | 129 (8.7) | 64 (4.3) | 46 (3.1) | 9 (1.5) | 17 (2.8) | 1 (0.2) |
| HPV 45 | 39 (2.6) | 20 (1.3) | 13 (0.9) | 9 (1.5) | 16 (2.6) | 4 (0.7) |
| HPV 51 | 355 (23.8) | 198 (13.3) | 159 (10.7) | 31 (5.1) | 56 (9.1) | 9 (1.5) |
| HPV 52 | 288 (19.3) | 160 (10.7) | 131 (8.8) | 18 (2.9) | 40 (6.5) | 7 (1.1) |
| HPV 56 | 176 (11.8) | 102 (6.8) | 77 (5.2) | 12 (2.0) | 23 (3.8) | 2 (0.3) |
| HPV 58 | 63 (4.2) | 30 (2.0) | 24 (1.6) | 2 (0.3) | 6 (1.0) | 0 (0.0) |
| HPV 59 | 72 (4.8) | 33 (2.2) | 20 (1.3) | 5 (0.8) | 15 (2.4) | 0 (0.0) |
| Low risk types | | | | | | |
| HPV 6 | 183 (12.3) | 148 (9.9) | 107 (7.2) | 43 (7.0) | 80 (13.0) | 17 (2.8) |
| HPV 11 | 31 (2.1) | 14 (0.9) | 13 (0.9) | 22 (3.6) | 48 (7.8) | 13 (2.1) |
| HPV 34 | 18 (1.2) | 5 (0.3) | 2 (0.1) | 1 (0.2) | 2 (0.3) | 0 (0.0) |
| HPV 40 | 39 (2.6) | 23 (1.5) | 13 (0.9) | 5 (0.8) | 11 (1.8) | 0 (0.0) |
| HPV 42 | 27 (1.8) | 6 (0.4) | 2 (0.1) | 1 (0.2) | 1 (0.2) | 0 (0.0) |
| HPV 43 | 60 (4.0) | 38 (2.6) | 24 (1.6) | 16 (2.6) | 10 (1.6) | 2 (0.3) |
| HPV 44 | 50 (3.4) | 31 (2.1) | 24 (1.6) | 9 (1.5) | 10 (1.6) | 0 (0.0) |
| HPV 53 | 259 (17.4) | 155 (10.4) | 115 (7.7) | 13 (2.1) | 33 (5.4) | 3 (0.5) |
| HPV 54 | 121 (8.1) | 51 (3.4) | 29 (1.9) | 12 (2.0) | 10 (1.6) | 0 (0.0) |
| HPV 66 | 223 (15.0) | 127 (8.5) | 99 (6.6) | 23 (3.8) | 37 (6.0) | 8 (1.3) |
| HPV 68 | 79 (5.3) | 35 (2.4) | 24 (1.6) | 11 (1.8) | 18 (2.9) | 3 (0.5) |
| HPV 70 | 27 (1.8) | 11 (0.7) | 6 (0.4) | 2 (0.3) | 6 (1.0) | 0 (0.0) |
| HPV 74 | 65 (4.4) | 35 (2.4) | 23 (1.5) | 5 (0.8) | 17 (2.8) | 1 (0.2) |

Note: The analyses are based on 1,492 women and 614 MSM with genital and anal samples collected in 2009, 2011, 2013, 2015, 2017 or 2019.

1. Irrespective of anal HPV infection.
2. Irrespective of genital HPV infection.
3. Positive for at least one genotype.

Abbreviations: HPV = human papillomavirus, MSM = men who have sex with men.



Supplementary Figure 2: Flowchart with the overview of number of participants or records per analysis for calculation of the concordance between anogenital sites and assessing risk factors for concurrent anogenital detection among women recruited at sexual health clinics in the Netherlands, 2009-2019